Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$58.21 -2.5%	$53.49	$30.04 ▼ $71.13	$5.30B	1.8	2.62 million shs	1.44 million shs
EVTCY Evotec	$3.76 -1.6%	$4.07	$14.22 ▼ $26.57	$1.24B	0.98	2,407 shs	43,217 shs
MRUS Merus	$66.11 -1.7%	$58.88	$33.19 ▼ $67.59	$5.00B	1.09	873,812 shs	148,736 shs
NUVL Nuvalent	$74.83 -1.6%	$78.87	$55.53 ▼ $113.51	$5.39B	1.3	541,885 shs	252,831 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	0.00%	+8.60%	-8.29%	+54.42%	+24.83%
EVTCY Evotec	0.00%	-4.33%	-11.32%	-7.39%	+15.34%
MRUS Merus	0.00%	+5.08%	+6.31%	+62.60%	+30.18%
NUVL Nuvalent	0.00%	+2.60%	-8.82%	+3.72%	+6.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	3.203 of 5 stars	3.3	3.0	0.0	0.0	3.3	3.3	0.6
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MRUS Merus	1.937 of 5 stars	3.5	1.0	0.0	0.0	1.9	2.5	0.0
NUVL Nuvalent	3.048 of 5 stars	4.5	1.0	0.0	0.0	2.0	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.50	Moderate Buy	$71.60	23.00% Upside
EVTCY Evotec	0.00	N/A	N/A	N/A
MRUS Merus	3.09	Buy	$88.50	33.88% Upside
NUVL Nuvalent	3.09	Buy	$119.60	59.83% Upside

Current Analyst Ratings Breakdown

Latest EVTCY, NUVL, CRSP, and MRUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/6/2025	MRUS Merus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$97.00 ➝ $96.00
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00
7/22/2025	CRSP CRISPR Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$79.00 ➝ $78.00
7/21/2025	NUVL Nuvalent	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$115.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/30/2025	NUVL Nuvalent	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00

(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	141.90	N/A	N/A	$22.64 per share	2.57
EVTCY Evotec	$572.16M	2.17	$0.04 per share	105.53	$2.52 per share	1.49
MRUS Merus	$36.13M	138.38	N/A	N/A	$9.46 per share	6.99
NUVL Nuvalent	N/A	N/A	N/A	N/A	$14.99 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	9.17	∞	N/A	20.85%	16.02%	7.81%	N/A
MRUS Merus	-$215.33M	-$5.50	N/A	N/A	N/A	-685.64%	-50.28%	-42.00%	10/30/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	N/A

Latest EVTCY, NUVL, CRSP, and MRUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/5/2025	Q1 2025	MRUS Merus	-$1.17	-$2.23	-$1.06	-$2.23	$9.77 million	$8.83 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	16.61	16.61
EVTCY Evotec	0.53	2.57	2.50
MRUS Merus	N/A	8.39	8.39
NUVL Nuvalent	N/A	13.57	13.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
EVTCY Evotec	N/A
MRUS Merus	96.14%
NUVL Nuvalent	97.26%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.10%
EVTCY Evotec	N/A
MRUS Merus	3.70%
NUVL Nuvalent	10.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.22 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
MRUS Merus	37	75.63 million	72.84 million	Optionable
NUVL Nuvalent	40	72.11 million	64.75 million	Optionable

EVTCY, NUVL, CRSP, and MRUS Headlines

Recent News About These Companies

Lord Abbett & CO. LLC Sells 112,621 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 18 at 5:26 AM | marketbeat.com

Citigroup Inc. Purchases 112,519 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 15 at 4:12 AM | marketbeat.com

Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium

August 13, 2025 | prnewswire.com

Wedbush Forecasts Nuvalent's Q3 Earnings (NASDAQ:NUVL)

August 11, 2025 | marketbeat.com

Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock

August 10, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Insider Henry E. Pelish Sells 5,500 Shares

August 9, 2025 | insidertrades.com

Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results

August 7, 2025 | prnewswire.com

Nuvalent (NUVL) Projected to Post Earnings on Thursday

August 7, 2025 | marketbeat.com

XTX Topco Ltd Acquires New Stake in Nuvalent, Inc. (NASDAQ:NUVL)

August 5, 2025 | marketbeat.com

Jefferies Financial Group Inc. Acquires 23,795 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 4, 2025 | marketbeat.com

Nuvalent, Inc. (NASDAQ:NUVL) Given Average Recommendation of "Buy" by Brokerages

August 4, 2025 | marketbeat.com

TD Asset Management Inc Purchases 23,412 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

August 3, 2025 | marketbeat.com

Nuvalent (NUVL) Gets a Buy from Goldman Sachs

July 30, 2025 | theglobeandmail.com

Victory Capital Management Inc. Has $1.88 Million Stake in Nuvalent, Inc. (NASDAQ:NUVL)

July 30, 2025 | marketbeat.com

Universal Beteiligungs und Servicegesellschaft mbH Sells 11,308 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

July 29, 2025 | marketbeat.com

Nuvalent Doses First Patient in Phase 3 ALKAZAR Trial for Neladalkib in ALK-Positive NSCLC

July 25, 2025 | msn.com

Legato Capital Management LLC Has $629,000 Holdings in Nuvalent, Inc. (NASDAQ:NUVL)

July 25, 2025 | marketbeat.com

New York State Common Retirement Fund Buys 3,965 Shares of Nuvalent, Inc. (NASDAQ:NUVL)

July 25, 2025 | marketbeat.com

Nuvalent (NASDAQ:NUVL) Given Outperform Rating at Wedbush

July 21, 2025 | marketbeat.com

Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial

July 21, 2025 | tipranks.com

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC

July 21, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EVTCY, NUVL, CRSP, and MRUS Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$58.21 -1.52 (-2.54%)

As of 03:10 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Evotec OTCMKTS:EVTCY

$3.76 -0.06 (-1.57%)

As of 08/15/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Merus NASDAQ:MRUS

$66.10 -1.15 (-1.70%)

As of 03:10 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Nuvalent NASDAQ:NUVL

$74.83 -1.21 (-1.59%)

As of 03:10 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time